JP2019509286A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509286A5
JP2019509286A5 JP2018546864A JP2018546864A JP2019509286A5 JP 2019509286 A5 JP2019509286 A5 JP 2019509286A5 JP 2018546864 A JP2018546864 A JP 2018546864A JP 2018546864 A JP2018546864 A JP 2018546864A JP 2019509286 A5 JP2019509286 A5 JP 2019509286A5
Authority
JP
Japan
Prior art keywords
composition
crystalline form
form according
chloro
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546864A
Other languages
English (en)
Japanese (ja)
Other versions
JP7306828B2 (ja
JP2019509286A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021172 external-priority patent/WO2017156009A1/en
Publication of JP2019509286A publication Critical patent/JP2019509286A/ja
Publication of JP2019509286A5 publication Critical patent/JP2019509286A5/ja
Priority to JP2021177448A priority Critical patent/JP2022017433A/ja
Application granted granted Critical
Publication of JP7306828B2 publication Critical patent/JP7306828B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546864A 2016-03-08 2017-03-07 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用 Active JP7306828B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021177448A JP2022017433A (ja) 2016-03-08 2021-10-29 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662305393P 2016-03-08 2016-03-08
US62/305,393 2016-03-08
US201662346336P 2016-06-06 2016-06-06
US62/346,336 2016-06-06
PCT/US2017/021172 WO2017156009A1 (en) 2016-03-08 2017-03-07 Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021177448A Division JP2022017433A (ja) 2016-03-08 2021-10-29 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用

Publications (3)

Publication Number Publication Date
JP2019509286A JP2019509286A (ja) 2019-04-04
JP2019509286A5 true JP2019509286A5 (https=) 2020-04-02
JP7306828B2 JP7306828B2 (ja) 2023-07-11

Family

ID=58387911

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018546864A Active JP7306828B2 (ja) 2016-03-08 2017-03-07 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用
JP2021177448A Pending JP2022017433A (ja) 2016-03-08 2021-10-29 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021177448A Pending JP2022017433A (ja) 2016-03-08 2021-10-29 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用

Country Status (30)

Country Link
US (6) US10100021B2 (https=)
EP (1) EP3408260B1 (https=)
JP (2) JP7306828B2 (https=)
KR (2) KR20220035991A (https=)
CN (1) CN108779084A (https=)
AU (1) AU2017229466C1 (https=)
CA (1) CA3015505C (https=)
CL (1) CL2018002539A1 (https=)
CO (1) CO2018010568A2 (https=)
CY (1) CY1124397T1 (https=)
DK (1) DK3408260T3 (https=)
ES (1) ES2880123T3 (https=)
HR (1) HRP20211169T1 (https=)
HU (1) HUE055546T2 (https=)
IL (1) IL261244B (https=)
LT (1) LT3408260T (https=)
MX (1) MX377177B (https=)
MY (1) MY198185A (https=)
PH (1) PH12018501876A1 (https=)
PL (1) PL3408260T3 (https=)
PT (1) PT3408260T (https=)
RS (1) RS62172B1 (https=)
RU (1) RU2756223C2 (https=)
SA (1) SA518392325B1 (https=)
SG (1) SG11201807591VA (https=)
SI (1) SI3408260T1 (https=)
SM (1) SMT202100434T1 (https=)
TW (1) TWI731943B (https=)
WO (1) WO2017156009A1 (https=)
ZA (1) ZA201805840B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7306828B2 (ja) 2016-03-08 2023-07-11 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用
CN115487175B (zh) 2019-09-20 2024-05-14 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
KR102485499B1 (ko) * 2022-07-15 2023-01-09 오가노이드사이언스 주식회사 신장 질환의 치료 또는 예방용 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
US4206232A (en) 1976-05-10 1980-06-03 E. R. Squibb & Sons, Inc. Relieving hypertension with carboxyalkylacylamino acids
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4906615A (en) 1980-12-18 1990-03-06 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4939261A (en) 1984-06-08 1990-07-03 Ciba-Geigy Corporation N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase
EP0225292A3 (en) 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
KR880007441A (ko) 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
FR2623498B1 (fr) 1987-11-24 1990-04-06 Bioprojet Soc Civ Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
GB8820844D0 (en) 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US5599951A (en) 1989-09-15 1997-02-04 Societe Civile Bioprojet Amino acid derivatives, the process for their preparation and their applications to therapy
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5155100A (en) 1991-05-01 1992-10-13 Ciba-Geigy Corporation Phosphono/biaryl substituted dipeptide derivatives
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5977075A (en) 1995-04-21 1999-11-02 Novartis Ag N-aroylamino acid amides as endothelin inhibitors
US6660756B2 (en) 2001-03-28 2003-12-09 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007098042A2 (en) 2006-02-17 2007-08-30 Monsanto Technology Llc Chimeric regulatory sequences comprising introns from dicotyledons for plant gene expression
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
PH12012502091A1 (en) 2007-01-12 2019-06-14 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
AR070176A1 (es) 2008-01-17 2010-03-17 Novartis Ag Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
SG176009A1 (en) * 2009-05-28 2011-12-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
AU2011207020B2 (en) 2010-01-22 2014-04-17 Novartis Ag Intermediates of neutral endopeptidase inhibitors and preparation method thereof
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CA2819153A1 (en) 2010-12-15 2012-06-21 Theravance, Inc. Neprilysin inhibitors
HUE028051T2 (hu) 2010-12-15 2016-11-28 Theravance Biopharma R&D Ip Llc Neprilizin inhibitorok
JP5959065B2 (ja) * 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JP5959066B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JP5959074B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
CN103582630B (zh) 2011-05-31 2016-08-17 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
CA2871292A1 (en) 2012-05-31 2013-12-05 Theravance Biopharma R&D Ip, Llc Nitric oxide donor neprilysin inhibitors
WO2013184898A1 (en) 2012-06-08 2013-12-12 Theravance, Inc. Neprilysin inhibitors
SMT201700306T1 (it) 2012-06-08 2017-07-18 Theravance Biopharma R&D Ip Llc Inibitori di neprilisina
MX366149B (es) * 2012-08-08 2019-06-28 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina.
KR101811549B1 (ko) * 2013-06-19 2017-12-26 에프. 호프만-라 로슈 아게 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체
CA2934936A1 (en) * 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
JP7306828B2 (ja) 2016-03-08 2023-07-11 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用

Similar Documents

Publication Publication Date Title
JP6634368B2 (ja) 複素環式化合物及びそれらの使用
TWI657826B (zh) Complex of angiotensin II receptor antagonist metabolite and NEP inhibitor and preparation method thereof
TW200927125A (en) Salt form
ES2972295T3 (es) Sales de 2-(tert-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
JP2019509286A5 (https=)
JP2019501216A5 (https=)
TW200827326A (en) Organic compounds
JP2010516702A5 (https=)
JP2022532404A5 (https=)
TW201720444A (zh) 含有2-{4-[n-(5,6-二苯基吡 -2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物
JP2009534373A5 (https=)
TW202412769A (zh) Glp1錠劑組合物
WO2016051393A2 (en) Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
JP2018507207A5 (https=)
RU2018135072A (ru) Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения
RU2017132430A (ru) (2r,4r)-5-(5′-хлор-2′-фторбифенил-4-ил)-2-гидрокси-4-[(5-метилоксазол-2-карбонил)амино]пентановая кислота
JP6473820B2 (ja) 塩酸ヨンケナフィルの多形体及びその調製方法、組成物並びに用途
CN110520425B (zh) EOC315 Mod.I晶型化合物及其制备方法
CN103880829B (zh) 一种阿齐沙坦晶体及其制备方法和用途
JP2013014547A (ja) カンデサルタンシレキセチルを安定化した組成物及びその製造方法
JP2008505935A5 (https=)
CN104628708A (zh) 一种阿伐那非的晶型及其制备方法、用途和药物组合物
US9364475B2 (en) Tablet formulation of a phosphatidylinositol 3-kinase inhibitor
CN106715404A (zh) 无水结晶游离碱形式的6‑{2‑[1‑(6‑甲基‑3‑哒嗪基)‑4‑哌啶基]乙氧基}‑3‑乙氧基‑1，2‑苯并异噁唑